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Forty-seven patients presenting with primary human immunodeficiency virus (HIV) infec-
tion were treated with zidovudine 200 mg 3 times a day, lamivudine 150 mg 2 times a day,
and indinavir 800 mg 3 times a day for 1 year. From a mean pretreatment viral RNA level
of 4.93 log10 copies/mL, the proportions of patients having !500 copies/mL at 24 and 52 weeks
were 92.0% and 89.2%, respectively. For the 35 patients with data available at 24 and 52 weeks,
the corresponding proportions for the !50 copies/mL analysis were 86.6% and 79.3%, re-
spectively. The change in virus load was 22.19 and 22.41 log10 copies/mL at weeks 8 and 52,
respectively. CD4 cell counts increased, from a mean of 546 cells/mm3, by 142 cells/mm3 at
week 24 and by 210 cells/mm3 at week 52. Three patients discontinued the study because of
drug-related toxicity. Six (12.8%) patients had adverse experiences associated with nephroli-
thiasis. Combination therapy with zidovudine, lamivudine, and indinavir during primary HIV
infection results in a profound and sustained reduction in virus load with concurrent recovery
of the CD4 cell population.
Primary human immunodeficiency virus (HIV) infection rep-
resents a dynamic phase of HIV-1 infection: an intact immune
system is challenged with a rapidly replicating lentivirus that
preferentially infects and destroys cells that coordinate the
host’s ability to respond to the virus [1]. After primary infection,
it is thought that most of the immunopathological processes
that will eventually lead to AIDS have been established [2]. It
is during this primary infection phase that long-lived CD41
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lymphocytes become infected with HIV [3], making viral erad-
ication unlikely, even with years of potent antiretroviral therapy.
The immunological and virological outcomes following pri-
mary infection are thought to determine the rate of subsequent
disease progression [4]. Increased severity of symptoms and
signs of primary HIV infection, low CD4 nadir, and high levels
of circulating plasma HIV RNA following the seroconversion
illness are all associated with rapid disease progression [5]. This
would suggest that those patients presenting or identified with
an illness associated with primary HIV infection are likely to
show rapid progression of the disease, providing a theoretical
rationale for initiation of antiretroviral therapy during primary
HIV-1 infection. Zidovudine, lamivudine, and indinavir have
demonstrated clinical, immunological, and virological benefit
in chronic HIV infection [6]. We therefore evaluated this an-
tiretroviral combination in patients diagnosed with primary
HIV-1 infection.
Methods
A multinational open-label study was conducted at 6 sites in the
United States, Europe, and Australia. The study objective was to
evaluate the efficacy of zidovudine, lamivudine, and indinavir, as
measured by the rate of suppression of serum HIV RNA to below
the level of detection. The secondary objective was to evaluate the
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Figure 1. Results of intention-to-treat analysis, showing proportions (%) of patients with viral RNA levels of !500 and !50 copies/mL. Vertical
bars, 95% confidence intervals.
safety and tolerability of this combination in patients with primary
HIV infection. The protocol was approved by an institutional re-
view board for each site.
Study population. For the purposes of this study, primary HIV
infection was defined as at least 1 clinical and 1 laboratory feature
of primary infection. Clinical criteria included symptoms and signs
of acute retroviral syndrome, history of such symptoms within the
past 70 days, or exposure within the past 3 months and a negative
antibody test within the past 6 months. Laboratory criteria were
detectable HIV RNA in either plasma or serum, an indeterminate
Western blot test, a negative EIA, or a low-positive EIA with in-
creasing reactivity over time. All patients had to be 118 years of
age, with no pulmonary infections within the past 21 days and
routine laboratory parameters not 11.5 times the upper limit of
normal. All women of childbearing potential were required to have
a negative pregnancy test before enrollment.
Study medications were as follows: zidovudine 200 mg 3 times
a day, lamivudine 150 mg 2 times a day, and indinavir 800 mg 3
times a day. In instances of zidovudine intolerance, we permitted
substitution with stavudine. Patients were assessed weekly for the
first 4 weeks, then monthly through the first year.
Laboratory assessments. Samples were collected for centralized
batch testing of viral RNA (vRNA) with both the Roche Amplicor
assay (detection level 500 RNA copies/mL) and the ultradirect
assay (detection level 50 RNA copies/mL) (Amplicor; Roche Di-
agnostic Systems, Branchburg, NJ). CD41 and CD31 lymphocytes
were assessed locally with flow cytometric assays.
Adherence assessment. Patients returned all unused medication
for counting at each subsequent visit and documented, on diary
cards, all doses they ingested.
Statistical analyses. The primary efficacy analysis evaluated
the proportions of patients with vRNA levels of !500 copies/mL
(Amplicor assay) at each week of the study. Secondary analyses
focused on the proportions of patients with vRNA levels of !50
copies/mL (ultradirect assay) and on changes from baseline in
vRNA and CD4 cell count. The data were analyzed with intention-
to-treat model-based approaches. Specifically, for the analyses of
proportions of patients with vRNA levels of !500 and !50 copies/
mL, patients who discontinued the study for therapy-related rea-
sons (adverse experience or poor vRNA response) were scored as
virologic failures from the time of discontinuation onward, and the
required proportions were then determined by use of a longitudinal
generalized estimating equations approach [7] that also used avail-
able data for patients who discontinued therapy for nontherapy-
related reasons. A similar approach was used for the CD4 and
vRNA change from baseline analyses. For the latter, to calculate
changes from baseline only, a value of 500 was used for vRNA
assay results reported as !500 copies/mL, and a value of 250 was
used for results reported as negative (i.e., no amplifiable signal).
Because stavudine could be substituted for zidovudine as part
of toxicity management, it was not possible to calculate adherence
for zidovudine. Adherence was measured for indinavir and lami-
vudine with the following equation: percentage compliance p
doses taken while on study/total dose that could have100 3 (total
been taken, assuming that there was no change in dosing). Cu-
mulative frequency distributions for percentage compliance were
then graphed separately for each drug.
Results
Forty-seven patients were enrolled in the following cities:
New York, 12; Seattle, 10; Sydney, 8; Geneva, 6; Brussels, 4;
Basel, 3; Zurich, 2; and Milan, 2. Only 3 women were enrolled.
The mean age of participants was 32 years (range, 20–59 years),
and the majority of patients ( ) were white. Forty patientsn p 42
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Figure 2. Cumulative frequency distribution of percentage compliance with indinavir treatment
had typical symptoms of primary HIV infection, either at
screening (21) or within the past 70 days (19); 4 patients were
asymptomatic but had a negative test within the past 6 months.
Of these 47 subjects, 37 (79%) completed 52 weeks of treatment
with zidovudine (or stavudine), lamivudine, and indinavir; 10
(21%) patients discontinued because of adverse events ( ),n p 3
withdrawal from study ( ), or loss to follow-up ( ).n p 5 n p 2
No patient discontinued therapy because of virological failure.
Virological response. Expressed as change from a mean
baseline of 4.93 log10 copies/mL (SD, 0.97 log10 copies/mL;
range, 2.79–6.93 log10 copies/mL), there was a mean drop of
1.85 log10 copies/mL at week 4, 2.33 log10 copies/mL at week
24, and 2.41 log10 copies/mL at week 52.
The proportions of patients with a vRNA level of !500 cop-
ies/mL, found by use of the model-based approach, are shown
in figure 1. In this analysis, the proportions of patients with a
vRNA level of !500 copies/mL were 92% at 24 weeks and 89.8%
at 52 weeks. Corresponding proportions for the !50 copies/mL
analysis (figure 1) were 86.6% at 24 weeks and 79.3% at 52
weeks (because the ultradirect assay was not performed at 1
site with 12 patients, this figure is based on 35 patients). There
were no subjects continuing on protocol therapy who had in-
creasing HIV RNA levels.
Immunological response. CD4 counts increased rapidly af-
ter initiation of treatment, with a model-based increase of 103
cells/mm3 by week 2 from a baseline of 535 cells/mm3 (SD,
175.3 cells/mm3). By week 32, the estimated increase had almost
doubled to 211 cells/mm3. This increase was essentially main-
tained through week 52 (210 cells/mm3 above baseline).
Safety. All 47 patients in the study had at least 1 clinical
adverse experience during the trial; 45 of these were judged to
be possibly, probably, or definitely related to study drugs. Three
(6.4%) patients had clinical serious adverse experiences. Renal
colic requiring hospitalization 4 months after therapy initiation
in 1 patient (attributed to indinavir) and a constellation of
asthenia/fatigue, myalgia, headache, and anemia 4 months after
therapy began in a second patient were judged to be definitely
drug related; we attributed them to zidovudine. A third patient
with a history of depression experienced aggressive behavior 5
months after therapy initiation; this patient attempted suicide
with an overdose of study drugs 10 months into the study. This
event was not felt to be related to the study therapy. One of 3
patients with serious adverse experiences and an additional 2
subjects withdrew from the trial because of nausea or flank
pain. Clinical or laboratory evidence felt to be related to ne-
phrolithiasis was noted in 6 (12.8%) patients. The most common
(120% incidence) adverse experiences considered to be drug
related included fatigue or asthenia, abdominal pain, diarrhea,
nausea, vomiting, headache, and dry skin. Although it was not
prospectively addressed in this study, clinical features of lipo-
dystrophy were noted in 1 subject.
No patient died during this study. No HIV progression to
Centers for Disease Control and Prevention category B or C
[8] occurred during the study, although the patient who dis-
continued therapy because of renal colic developed herpetic
esophagitis 56 weeks after discontinuing all antiretroviral drugs.
Adherence. Adherence ( ) to the 3-times-a-daymean 5 SD
regimen for indinavir during the 52-week study period was
and for lamivudine. Figure 292.2% 5 13.5% 93.0% 5 15.4%
is a graph of the cumulative frequency distributions for indi-
navir adherence. Seventy-five percent of patients who received
indinavir and lamivudine were at least 99% adherent, as as-
sessed by pill counts of returned medication. A total of 17%
of patients had !80% adherence with indinavir, and 13% of
patients were !80% adherent with the twice-daily lamivudine.
No association was found between compliance and a plasma
virus load of !500 copies/mL at week 52 or at time of study
drop out. Surprisingly, 6 of 8 subjects with poor compliance
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(!80% indinavir compliance) had a virus load of !500 copies/
mL at study completion or at time of discontinuation, sug-
gesting that, among these patients, good virological suppression
could be achieved despite suboptimal compliance.
Discussion
This study illustrates the rapid and sustained reduction in
HIV RNA after initiation of combination antiretroviral therapy
during primary HIV-1 infection. More than 90% of subjects
achieved vRNA levels of !500 copies/mL within 12 weeks of
beginning therapy and maintained virus suppression through-
out follow-up. Commensurate with this reduction in circulating
virus was a resurgence of CD41 lymphocytes. There was a rapid
increase of ∼100 CD41 cells at week 2, followed by a more
gradual recovery throughout the remainder of follow-up.
Although all subjects enrolled in this trial reported some
clinically adverse experiences, there were few drug-related se-
rious adverse experiences. Only 3 (6.4%) of 47 subjects discon-
tinued therapy because of drug-related clinical experiences. Fa-
tigue and gastrointestinal symptoms were common but did not
appear to decrease adherence to therapy or to impact the vi-
rologic response to therapy.
Interestingly, in patients starting their first antiretroviral com-
bination, adherence in this study was high, with 75% of patients
reporting at least 99% adherence to indinavir. The absence of
virologic failures in this study may be attributed in part to
excellent adherence with this regimen. A recent study of zi-
dovudine, lamivudine, and ritonavir in patients with primary
HIV infection concluded that adherence in the setting of pa-
tients undergoing seroconversion was difficult, with 5 (41.7%)
of 12 patients in that study remaining on combination regimens
at 12 months [9].
Aggressive combination treatment for primary HIV infection
has become a standard recommendation [10], despite the lack
of clinical trial data supporting this approach. Nonrandomized
open-label studies of combination therapy during primary HIV
infection have suggested that patients at this phase of infection
respond well to treatment [11]. Unfortunately, increasing aware-
ness of long-term toxicities seen with antiretroviral therapy is
a concern [12], particularly if these patients are expected to
remain on therapy indefinitely.
The perceived sense of urgency in treating patients with pri-
mary HIV infection was originally based on the supposition
that such patients may be able to achieve viral eradication if
treatment were initiated early enough and continued for long
enough [13]. Unfortunately, the discovery of long-lived latently
infected lymphocytes has made viral eradication with antire-
troviral agents an unachievable goal at present [5]. Others have
argued that initiating treatment during primary infection may
be the only way to preserve HIV-specific T cell function [1],
possibly allowing discontinuation of therapy at some future
time. Rapid viral rebound and possible recurrence of symp-
tomatic primary HIV infection has been noted on discontin-
uation of treatment [14]. Alternatively, the significance of an
anecdotal report of a recently infected patient remaining in
virological remission after stopping therapy has also been
widely debated [15]. Whether early aggressive treatment of pri-
mary HIV infection will ultimately alter the course of disease
is yet to be determined; further studies of immediate versus
deferred therapy are needed to evaluate this potential.
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